{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:47:56Z","timestamp":1792421276715,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001697","name":"Keio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.alit.2024.10.009","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:33:11Z","timestamp":1733229191000},"page":"274-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0909-9409","authenticated-orcid":false,"given":"Katsunori","family":"Masaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Suzukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-5731","authenticated-orcid":false,"given":"Norihiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-9815","authenticated-orcid":false,"given":"Yasunari","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Tagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9595-9657","authenticated-orcid":false,"given":"Masayuki","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-5901","authenticated-orcid":false,"given":"Hiroyuki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Hiranuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Gon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8853-6149","authenticated-orcid":false,"given":"Hiroki","family":"Kabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-1702","authenticated-orcid":false,"given":"Jun","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2024.10.009_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2024.10.009_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.10.009_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.alit.2020.08.001","article-title":"Japanese guidelines for adult asthma 2020","volume":"69","author":"Nakamura","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.10.009_bib4","unstructured":"Ministry of Health, Labour and Welfare of Japan. [Overview of Patient Survey in 2020] (in Japanese). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/10syoubyo\/dl\/r02syobyo.pdf [Accessed 12 November 2024]."},{"key":"10.1016\/j.alit.2024.10.009_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.alit.2019.06.003","article-title":"Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.10.009_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jaci.2010.07.019","article-title":"Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma","volume":"126","author":"Bousquet","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.10.009_bib7","first-page":"848","article-title":"Economic burden of illness among patients with severe asthma in a managed care setting","volume":"22","author":"Chastek","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.alit.2024.10.009_bib8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2024.10.009_bib9","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2024.10.009_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.10.009_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2024.10.009_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.10.009_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of Italian severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2024.10.009_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/biom13030538","article-title":"Pretreatment frequency of circulating Th17 cells and FeNO levels predicted the real-world response after 1 year of benralizumab treatment in patients with severe asthma","volume":"13","author":"Sandhu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.alit.2024.10.009_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107285","article-title":"Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: findings from CHRONICLE","volume":"216","author":"Panettieri","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2024.10.009_bib16","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.jaip.2023.05.041","article-title":"Real-world effectiveness of IL-5\/5Ra targeted biologics in severe eosinophilic asthma with comorbid bronchiectasis","volume":"11","author":"Bendien","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.10.009_bib17","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jaip.2023.04.029","article-title":"Real-world effectiveness study of benralizumab for severe eosinophilic asthma: ZEPHYR 2","volume":"11","author":"Carstens","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.10.009_bib18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib19","first-page":"4362","article-title":"Benralizumab in patients with severe eosinophilic asthma: a multicentre real-life experience","volume":"12","author":"Scioscia","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.alit.2024.10.009_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/JAA.S295676","article-title":"Real-world experience with benralizumab in patients with severe eosinophilic asthma: a case series","volume":"14","author":"Menzella","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2021.02.048","article-title":"Real-world effectiveness of anti-IL-5\/5R therapy in severe atopic eosinophilic asthma with fungal sensitization","volume":"9","author":"Dhariwal","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.10.009_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months","volume":"14","author":"Kayser","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib24","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.10.009_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4081\/mrm.2021.785","article-title":"Real world effectiveness of benralizumab on respiratory function and asthma control","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.alit.2024.10.009_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)","volume":"21","author":"Mart\u00ednez-Morag\u00f3n","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.alit.2024.10.009_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","article-title":"Real-world effectiveness of benralizumab: results from the ZEPHYR 1 study","volume":"128","author":"Chung","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.10.009_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JAA.S358738","article-title":"Reliability, satisfaction and effectiveness of benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the Auto-Benra Study","volume":"15","author":"Garc\u00eda-Moguel","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.15586\/aei.v51i6.852","article-title":"Benralizumab in severe eosinophilic asthma: a real-world, single-center, observational study from Mexico","volume":"51","author":"Luis","year":"2023","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.alit.2024.10.009_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6 months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.alit.2024.10.009_bib31","unstructured":"Ministry of Health, Labour and Welfare of Japan. [Summary of Patient Survey 2020] (in Japanese). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/20\/dl\/toukei.pdf [Accessed 12 November 2024]."},{"key":"10.1016\/j.alit.2024.10.009_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JAA.S432695","article-title":"Real-world safety and effectiveness of benralizumab in Japanese patients with severe asthma: a multicenter prospective observational study","volume":"17","author":"Yamaguchi","year":"2024","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.rmed.2005.08.012","article-title":"Identifying \u2018well-controlled\u2019 and \u2018not well-controlled\u2019 asthma using the Asthma Control Questionnaire","volume":"100","author":"Juniper","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2024.10.009_bib34","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib35","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib36","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.10.009_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.alit.2017.10.004","article-title":"Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma","volume":"67","author":"Ohta","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.10.009_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2332\/allergolint.10-OA-0277","article-title":"Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects","volume":"60","author":"Matsunaga","year":"2011","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.10.009_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.resinv.2020.05.006","article-title":"An official JRS statement: the principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice","volume":"59","author":"Matsunaga","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2024.10.009_bib40","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/biom13030538","article-title":"Pretreatment frequency of circulating Th17 cells and FeNO levels predicted the real-world response after 1 Year of benralizumab treatment in patients with severe asthma","volume":"13","author":"Sandhu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.alit.2024.10.009_bib41","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/JAA.S383012","article-title":"Clinical features and efficacy of benralizumab in patients with blood eosinophil count between 300 and 450 cells\/\u03bcl: a post hoc analysis from the ANANKE study","volume":"15","author":"Senna","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2024.10.009_bib42","article-title":"Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma","volume":"10","author":"Chan","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.alit.2024.10.009_bib43","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.10.009_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2213-2600(22)00185-0","article-title":"Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study","volume":"11","author":"Kole","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2024.10.009_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"Nagase","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.10.009_bib46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2024.10.009_bib47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/thoraxjnl-2020-216380","article-title":"Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales","volume":"76","author":"Davies","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2024.10.009_bib48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thoraxjnl-2020-216512","article-title":"Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data","volume":"76","author":"Shah","year":"2021","journal-title":"Thorax"}],"updated-by":[{"DOI":"10.1016\/j.alit.2025.05.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S132389302400128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S132389302400128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:41:59Z","timestamp":1747240919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S132389302400128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S132389302400128X"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2024.10.009","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}